カテゴリ： GlobalData, カナダ, 企業調査

ESSA Pharma Inc (EPI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：ESSA Pharma Inc (EPI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8268
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：43
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Essa Pharma Inc (Essa Pharma) is a drug developer that offers oncology therapeutics. The company develops EPI-506, disrupts androgen receptor transcriptional activity through selectively blocking the N-terminal domain of the AR. It also conducts research on prostate cancer and the androgen receptor, metastatic CRPC, and the androgen receptor as a therapeutic target. Essa Pharma’s EPI-506 is used treat medical and surgical therapies that decrease androgen levels. The company has collaboration with the cancer prevention and research institute to advance science for cancer biology developments. It operates in Canada and the US. Essa Pharma is headquartered in Vancouver, British Columbia, Canada.

ESSA Pharma Inc (EPI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ESSA Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Essa Pharma Files Registration Statement for Public Offering of Shares 11
Essa Pharma Raises USD20.3 Million in Public Offering of Shares 12
Essa Pharma Raises USD5 Million in Second Tranche of Private Placement of Shares 14
ESSA Pharma Prices Public Offering of Units 16
Essa Pharma Raises USD5 Million in Private Placement of Shares 17
ESSA Pharma Raises USD15 Million in Private Placement of Units 18
ESSA Pharma Raises USD12 Million in Private Placement of Warrants 20
ESSA Pharma Raises USD1.4 Million in Private Placement of Warrants 21
Essa Pharma Raises USD2 Million in Private Placement of Shares 22
Essa Pharma Raises USD1.8 Million in Private Placement of Shares 23
Debt Offering 24
Essa Pharma Raises USD0.8 Million in Private Placement of 12% Convertible Debentures 24
ESSA Pharma Inc – Key Competitors 25
ESSA Pharma Inc – Key Employees 26
ESSA Pharma Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 14, 2018: Essa Pharma provides corporate update and reports financial results for fiscal third quarter ended June 30, 2018 28
May 14, 2018: ESSA Pharma Announces Financial Results for Fiscal Second Quarter Ended March 31, 2018 29
Feb 13, 2018: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017 30
Dec 11, 2017: ESSA Pharma Announces Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2017 31
Aug 14, 2017: ESSA Pharma Provides Business Update and Announces Financial Results for the Fiscal Third Quarter Ended June 30, 2017 32
May 15, 2017: ESSA Pharma Provides Business Update and Announces Financial Results for the Second Quarter Ended March 31, 2017 33
Feb 13, 2017: ESSA Pharma Provides Business Update and Announces Financial Results for the First Quarter Ended December 31, 2016 35
Corporate Communications 37
Jan 25, 2018: ESSA Pharma Announces Management Changes 37
Nov 22, 2017: ESSA Pharma Announces New Listing on the TSX Venture Exchange Concurrent with Voluntary Delisting from the TSX 38
Product News 39
01/30/2017: Essa Receives US$4.0 Million Grant Payment From Cancer Prevention Research Institute Of Texas 39
Clinical Trials 40
May 17, 2017: ESSA Pharma Announces Data from Phase 1 Trial of EPI-506 to be Presented During 2017 ASCO Annual Meeting 40
Apr 05, 2017: ESSA Pharma Receives US$1.2 Million Grant Payment from Cancer Prevention Research Institute of Texas 41
Apr 03, 2017: ESSA Pharma Provides Clinical Study Update and Announces Presentations at the American Association for Cancer Research Annual Meeting 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ESSA Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ESSA Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Essa Pharma Files Registration Statement for Public Offering of Shares 11
Essa Pharma Raises USD20.3 Million in Public Offering of Shares 12
Essa Pharma Raises USD5 Million in Second Tranche of Private Placement of Shares 14
ESSA Pharma Prices Public Offering of Units 16
Essa Pharma Raises USD5 Million in Private Placement of Shares 17
ESSA Pharma Raises USD15 Million in Private Placement of Units 18
ESSA Pharma Raises USD12 Million in Private Placement of Warrants 20
ESSA Pharma Raises USD1.4 Million in Private Placement of Warrants 21
Essa Pharma Raises USD2 Million in Private Placement of Shares 22
Essa Pharma Raises USD1.8 Million in Private Placement of Shares 23
Essa Pharma Raises USD0.8 Million in Private Placement of 12% Convertible Debentures 24
ESSA Pharma Inc, Key Competitors 25
ESSA Pharma Inc, Key Employees 26
ESSA Pharma Inc, Subsidiaries 27

List of Figures
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ESSA Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ESSA Pharma Inc (EPI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Intra Energy Corporation Ltd (IEC)：電力：M&Aディール及び事業提携情報
    Summary Intra Energy Corporation Limited (IEC), formerly Atomic Resources Limited, is a mining and energy company that operates through subsidiaries, affiliates, and joint ventures. It explores and mines coal, mineral resources, ore reserves, and uranium through operating interests in various mines. …
  • Delta Corporation Limited：企業の戦略・SWOT・財務情報
    Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Ali Baba：企業の戦略・SWOT・財務情報
    Ali Baba - Strategy, SWOT and Corporate Finance Report Summary Ali Baba - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • HollyFrontier Corp (HFC)：石油・ガス：M&Aディール及び事業提携情報
    Summary HollyFrontier Corp (HollyFrontier) is an independent energy company. It carries out crude oil refining and wholesale marketing of refined petroleum products. The company produces and markets high-value light products such as gasoline, diesel, jet fuel, specialty lubricant products, heavy pro …
  • Duke University：企業のM&A・事業提携・投資動向
    Duke University - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Duke University Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Vitro, S.A.B. de C.V.：企業の戦略・SWOT・財務情報
    Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nezavisni operator sustava u Bosni i Hercegovini：企業の戦略的SWOT分析
    Nezavisni operator sustava u Bosni i Hercegovini - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competit …
  • Wilton Resources Inc (WIL)：石油・ガス：M&Aディール及び事業提携情報
    Summary Wilton Resources Inc (Wilton Resources) is an exploration and development company that develops oil and gas reserves. The company offers exploration of underdeveloped conventional and unconventional resources with prime focus on African continent. It operates in the process of acquiring oil …
  • Oswaldo Cruz Foundation：製薬・医療：M&Aディール及び事業提携情報
    Summary Oswaldo Cruz Foundation (Oswaldo Cruz) is a provider of research and development in biological sciences. It offers research programs and technological development projects in vaccines production, medications, drugs, reagents and diagnostic kits. The foundation provides research in experiment …
  • University Health Network：製薬・医療：M&Aディール及び事業提携情報
    Summary University Health Network (UHN) is a health care institution that provides patient care, research and educational services, and patient support services. It offers health care services such as palliative care, pharmacy and telehealth. UHN also provides specialized program services, accessibi …
  • Northern Biologics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Northern Biologics Inc (Northern Biologics) is a biotechnology company, which develops antibody-based- immuno-oncology medicines for treating cancers. Its pipeline product portfolio includes MSC-1, a first-in-class humanized antibody targeting leukemia inhibitory factor (LIF), a major immuno …
  • Valvoline Inc (VVV)：企業の財務・戦略的SWOT分析
    Valvoline Inc (VVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • AnaptysBio Inc (ANAB)：企業の財務・戦略的SWOT分析
    AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Dermira Inc (DERM)-医療機器分野：企業M&A・提携分析
    Summary Dermira Inc (Dermira) is a bio-pharmaceutical company which concentrates on the development and commercialization of novel therapies for the treatment of chronic skin conditions. The company concentrates on developing drugs for the treatment of diseases such as psoriasis, hyperhidrosis, atop …
  • Sandoz International GmbH-製薬・医療分野：企業M&A・提携分析
    Summary Sandoz International GmbH (Sandoz), a subsidiary of Novartis AG develops, manufactures and commercializes generic pharmaceutical products. The company provides biosimilars, generic antibiotics, dermatology and transplantation medicines. Its biosimilars comprise Omnitrope, Binocrit and Zarzio …
  • Diamondback Energy Inc (FANG)：企業の財務・戦略的SWOT分析
    Summary Diamondback Energy Inc (Diamondback Energy) operates as an oil and gas company that offers exploration and development programs. The company acquires, develops, explores and exploits unconventional, onshore oil and natural gas reserves in Permian Basin in West Texas. It develops the reserves …
  • Co-Diagnostics Inc-医療機器分野：企業M&A・提携分析
    Summary Co-Diagnostics Inc (Co-Diagnostics) is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company’s products include HCV RNA real-time PCR kit, HIV RNA real-time PCR kit, malaria DNA real-time PCR kit, and TB complex DNA kit …
  • Horizon Oil Ltd (HZN)：石油・ガス：M&Aディール及び事業提携情報
    Summary Horizon Oil Ltd (Horizon) is an oil and gas exploration and production company that acquires, explores, develops and produces oil and petroleum properties. The company holds interests in Maari and Manaia fields located in the Taranaki Basin approximately 80 kilometre offshore the north islan …
  • Traverse Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an privately held bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company provides lead candidate TRB-N0224 which is dev …
  • Rothschild Bank Ag：企業の戦略・SWOT・財務分析
    Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆